Salinomycin Selectively Targets ‘CD133+’ Cell Subpopulations and Decreases Malignant Traits in Colorectal Cancer Lines

Tao-Tao Dong,Hou-Min Zhou,Lin-Lin Wang,Bo Feng,Bo Lv,Min-Hua Zheng
DOI: https://doi.org/10.1245/s10434-011-1561-2
IF: 4.339
2011-01-01
Annals of Surgical Oncology
Abstract:Cancer stem-like cells (CSCs) in colorectal cancers (CRC) may account for the failure of treatments because they are resistant to many current anticancer therapies. Salinomycin, a potassium ionophore, was recently identified as a selective inhibitor of breast CSCs.
What problem does this paper attempt to address?